Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Redeeming Bonds for $66M

NEW YORK (GenomeWeb News) – Cellectis today announced it is redeeming all bonds issued on Nov. 3, 2011 into shares for a total of €50 million ($66 million).

The bonds were issued to FSI, or Fonds Stratégique d'Investissement, and industrialist Pierre Bastid.

The bonds are being redeemed into a total of 6.25 million shares of Cellectis stock at €8 per share. The redemption follows three consecutive trading days when Cellectis' stock exceeded €8 per share, the Paris-based gene engineering firm said.

Its board of directors is also issuing FSI and Bastid a total of 54,660 additional shares, split evenly between the two parties, of Cellectis stock at a price of €7.8392 per share, the company said.

After the redemption, Cellectis will have a total of 20.4 million outstanding shares. FSI and Bastid each hold almost 3.2 million shares, or about 15 percent of Cellectis' outstanding shares.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.